NDATOPICALCREAM
Approved
Jan 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
TRI-LUMA (fluocinolone acetonide, hydroquinone, and tretinoin) by Galderma is corticosteroid hormone receptor agonists [moa]. First approved in 2002.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRI-LUMA is a triple-combination topical cream combining fluocinolone acetonide (corticosteroid), hydroquinone (depigmenting agent), and tretinoin (retinoid) approved in 2002 for treatment of melasma and post-inflammatory hyperpigmentation. The product works through corticosteroid hormone receptor agonism combined with melanin suppression and skin cell turnover acceleration. It is administered as a topical cream applied directly to affected skin areas.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting team restructuring and transition planning in coming 12–24 months.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
Started Jan 2008
56 enrolled
Melasma
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
Started Nov 2006
340 enrolled
Melasma
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
Started Nov 2006
20 enrolled
Melasma
Career Relevance
TRI-LUMA offers limited career growth potential given its LOE-approaching lifecycle stage and minimal linked job openings (0 roles identified). Working on this product is best suited for professionals managing mature brands, executing cost-efficiency initiatives, and transitioning to pipeline roles.
Worked on TRI-LUMA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.